The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

Institution (Healthcare)

Homepage Wikipedia ROR

Also Known As

Arthur G. James Cancer Hospital, Arthur G. James Cancer Hospital and Richard J. Solove Research Institute, OSU Cancer Center, OSU Comprehensive Cancer Center, Richard J. Solove Research Institute, The James Cancer Hospital, The Ohio State University Cancer Center, The Ohio State University Comprehensive Cancer Center, The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute · Acronym: OSUCCC

7.4K

Publications

790.2K

Citations

402

Authors

953

Concepts

About

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute is a healthcare institution in Columbus, United States known for medicine, oncology, and cancer research.

Top Concepts

#	Concept	H-Index	Publications	Citations
1	Health Sciences	79	722	67.8K
2	Engineering	24	147	5.2K
3	Education	10	13	896
4	Management	3	3	112
5	Business	1	1	69

The Ohio State University Comprehensive Cancer Center – Arthur G. James Cancer Hospital and Richard J. Solove Research Institute

7.4K

Publications

790.2K

Citations

Page 1

	Year	Citations
PD-1 Blockade in Tumors with Mismatch-Repair Deficiency Dung T. Le, Jennifer N. Uram, Hao Wang, New England Journal of Medicine	2015	9.2K
Tisagenlecleucel in Adult Relapsed or Refractory Diffuse Large B-Cell Lymphoma Stephen J. Schuster, Michael Bishop, Constantine S. Tam, New England Journal of Medicine	2018	3.9K
Pan-cancer analysis of whole genomes Lauri A. Aaltonen, Federico Abascal, Adam Abeshouse, Nature	2020	3.1K
Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial Axel Grothey, Eric Van Cutsem, Alberto Sobrero, The Lancet OncologyGastrointestinal OncologyRegorafenib MonotherapyClinical TrialsColorectal Cancer	2012	2.8K
Global, Regional, and National Cancer Incidence, Mortality, Years of Life Lost, Years Lived With Disability, and Disability-Adjusted Life-Years for 29 Cancer Groups, 1990 to 2017 Christina Fitzmaurice, Degu Abate, Naghmeh Abbasi, JAMA Oncology	2019	2.6K
Incorporation of Bevacizumab in the Primary Treatment of Ovarian Cancer Robert A. Burger, Mark F. Brady, Michael A. Bookman, New England Journal of Medicine	2011	2.3K
An Intergroup Phase III Comparison of Standard Radiation Therapy and Two Schedules of Concurrent Chemoradiotherapy in Patients With Unresectable Squamous Cell Head and Neck Cancer David J. Adelstein, Yi Li, George L. Adams, Journal of Clinical Oncology	2002	1.7K
Colon Cancer, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology Al B. Benson, Alan P. Venook, Mahmoud M. Al-Hawary, Journal of the National Comprehensive Cancer Network	2021	1.7K
Rucaparib maintenance treatment for recurrent ovarian carcinoma after response to platinum therapy (ARIEL3): a randomised, double-blind, placebo-controlled, phase 3 trial Robert L. Coleman, Amit M. Oza, Domenica Lorusso, The Lancet Rucaparib Maintenance TreatmentMedicineRecurrent Ovarian CarcinomaGynecologyCancer Treatment	2017	1.7K
Breast Cancer, Version 3.2020, NCCN Clinical Practice Guidelines in Oncology William J. Gradishar, Benjamin O. Anderson, Jame Abraham, Journal of the National Comprehensive Cancer Network	2020	1.6K

Page 1